These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25278116)

  • 1. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.
    Centonze D
    Eur Neurol; 2014; 72 Suppl 1():6-8. PubMed ID: 25278116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.
    Di Marzo V
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):9-14. PubMed ID: 21449854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
    Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
    Russo M; Calabrò RS; Naro A; Sessa E; Rifici C; D'Aleo G; Leo A; De Luca R; Quartarone A; Bramanti P
    Neural Plast; 2015; 2015():656582. PubMed ID: 25699191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the management of MS spasticity: recent observational studies.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():12-4. PubMed ID: 25278118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spinal pathophysiology of spasticity--from a basic science point of view.
    Nielsen JB; Crone C; Hultborn H
    Acta Physiol (Oxf); 2007 Feb; 189(2):171-80. PubMed ID: 17250567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiology of spasticity].
    Marque P; Brassat D
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S36-44. PubMed ID: 22721363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
    Sastre-Garriga J; Vila C; Clissold S; Montalban X
    Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of repetitive transcranial magnetic stimulation (rTMS) for the treatment of spasticity.
    Mori F; Koch G; Foti C; Bernardi G; Centonze D
    Prog Brain Res; 2009; 175():429-39. PubMed ID: 19660671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. THC:CBD spray and MS spasticity symptoms: data from latest studies.
    Rekand T
    Eur Neurol; 2014; 71 Suppl 1():4-9. PubMed ID: 24457846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG; Vila C
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of spasticity in stroke.
    Burke D; Wissel J; Donnan GA
    Neurology; 2013 Jan; 80(3 Suppl 2):S20-6. PubMed ID: 23319482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.